Monday, November 12, 2018

Get the Edge
Click here to view an archive of:

Investment Education
Book Recommendations
Food for thought
Glimpses into EdgePointers' lives
...and Daily Musings

Today's links:

Things you see during every market correction (Link)

Biosimiliars to slash drug costs in rich countries ($) (Link)

"Biosimilars approvals are on the rise, promising cheaper biotech drugs in the long run.  The global market for them could triple to $15 billion by 2020, and could reduce U.S. healthcare spending by $54 billion over the next decade."

Growth of microbrands threatens consumer-goods giants ($) (Link)

"The growth of direct-to-consumer brands (Casper, Warby Parker, Glossier, etc.) is driving a significant shift in the consumer-goods sector, challenging established giants. The biggest food-and-beverage companies drove only 3% of total industry growth between 2011 and 2015 with a long tail of 20,000 companies below the top 100 producing half of all growth. The growth of "just-in-time" manufacturing means startups no longer need to splurge on inventory, and other service providers can pass on economies of scale once available only to giants. Microbrands can also sell their products through Amazon, and can use online ad platforms to target consumers with great accuracy. The giants are well aware of the threat, and in response are snapping up companies at high premiums."